Lisa Mobley
Psychiatric/Mental Health · Jacksonville, NCNPI 1700069044
Payments from drug & device makers
Across 410 payments — averaging $13.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$667
- AbbVie$664
- Alkermes, Inc.$598
- Vanda Pharmaceuticals Inc.$570
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$567
- Lundbeck LLC$456
- plus $2K from 10 others
What the payments were for
- Food & beverage$5,44799%
- Education$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 54 | $667 |
| AbbVie | 56 | $664 |
| Alkermes, Inc. | 40 | $598 |
| Vanda Pharmaceuticals Inc. | 38 | $570 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $567 |
| Lundbeck LLC | 25 | $456 |
| Teva Pharmaceuticals USA, Inc. | 50 | $408 |
| Johnson & Johnson | 18 | $379 |
| E.r. Squibb & Sons, L.L.C. | 24 | $336 |
| Axsome Therapeutics, Inc. | 19 | $318 |
| Neurocrine Biosciences, Inc. | 19 | $213 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $138 |
| Corium, LLC | 16 | $137 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $15 |
How this compares
$5,502 in reported general payments places this provider in the 90th percentile of 947 psychiatric/mental health providers in North Carolina.
See all psychiatric/mental health providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 19 | $150,684 |
| VraylarCariprazine Hcl | 93 | $147,796 |
| Invega SustennaPaliperidone Palmitate | 25 | $94,507 |
| RexultiBrexpiprazole | 53 | $79,053 |
| LybalviOlanzapine/Samidorphan Malate | 30 | $52,077 |
| TrintellixVortioxetine Hydrobromide | 67 | $39,701 |
| CaplytaLumateperone Tosylate | 16 | $27,708 |
| BelsomraSuvorexant | 36 | $17,140 |
| QelbreeViloxazine Hcl | 16 | $12,631 |
| Paliperidone ErPaliperidone | 46 | $8,126 |
| Lurasidone Hcl | 76 | $6,750 |
| Doxepin Hcl | 154 | $6,320 |
| Aripiprazole | 201 | $5,385 |
| FetzimaLevomilnacipran Hcl | 11 | $5,144 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 32 | $4,563 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $664 | $152,940104 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $213 | $150,68419 claims |
| Johnson & JohnsonInvega Sustenna | $379 | $94,50725 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $667 | $79,05353 claims |
| Alkermes, Inc.Lybalvi | $598 | $52,07730 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $138 | $39,70167 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $567 | $27,70816 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $17 | $12,63116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 947 psychiatric/mental health providers in North Carolina.
Other psychiatric/mental health in Jacksonville
- Pamela EdwardsJacksonville$16K
- Melvin JamesJacksonville$14K
- Nicole DunniganJacksonville$8K
- Ashleigh BrownJacksonville$7K
- Desiree MatthewsCharlotte$807K
- Benedetto PalomboCharlotte$671K
- Clarence RunnelsCreedmoor$339K
- Lisa SuddrethGastonia$111K
- April NandigamGreensboro$88K
- Hannah NealeyFuquay Varina$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.